© 2004 by Oxford University Press
© 2004 Oxford University Press
ARTICLE |
Phase III Randomized Trial of Docetaxel–Carboplatin Versus Paclitaxel–Carboplatin as First-line Chemotherapy for Ovarian Carcinoma
On behalf of the Scottish Gynaecological Cancer Trials Group
Affiliations of authors: Cancer Research U.K. Department of Medical Oncology, Glasgow, U.K. (PAV, JP, AH); Christie Hospital, Manchester, U.K. (GCJ); Sammons Cancer Center, Dallas, TX (AG); Hammermith Hospital, London, U.K. (HG); Weston Park Hospital, Sheffield, U.K. (RC); Belfast City Hospital, Northern Ireland, U.K. (RA); Aberdeen Royal Infirmary, Aberdeen, U.K. (DP); Royal Marsden Hospital, London, U.K. (SBK)
Correspondence to: Paul A. Vasey, MD, Division of Oncology, Joyce Tweddell Bldg., Royal Brisbane and Women's Hospital, Herston, Queensland 4029, Australia (e-mail: paul_vasey{at}health.qld.gov.au)
Background: Chemotherapy with a platinum agent and a taxane (paclitaxel) is considered the standard of care for treatment of ovarian carcinoma. We compared the combination of docetaxel–carboplatin with the combination of paclitaxel–carboplatin as first-line chemotherapy for stage Ic–IV epithelial ovarian or primary peritoneal cancer. Methods: We randomly assigned 1077 patients to receive docetaxel at 75 mg/m2 of body surface area (1-hour intravenous infusion) or paclitaxel at 175 mg/m2 (3-hour intravenous infusion). Both treatments then were followed by carboplatin to an area under the plasma concentration–time curve of 5. The treatments were repeated every 3 weeks for six cycles; in responding patients, an additional three cycles of single-agent carboplatin was permitted. Survival curves were calculated by the Kaplan–Meier method, and hazard ratios were estimated with the Cox proportional hazards model. All statistical tests were two-sided. Results: After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel–carboplatin and 14.8 months for paclitaxel–carboplatin; hazard ratio [HR] docetaxel–paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = –0.8%, 95% CI = –8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel–paclitaxel = –1.0%, 95% CI = –7.2% to 5.1%; P = .794) response rates. However, docetaxel–carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel–carboplatin (grade 
2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade 2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001). Treatment with docetaxel–carboplatin was associated with statistically significantly more grade 3–4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel–carboplatin, although myelosuppression did not influence dose delivery or patient safety. Global quality of life was similar in both arms, but substantive differences in many symptom scores favored docetaxel. Conclusions: Docetaxel–carboplatin appears to be similar to paclitaxel–carboplatin in terms of progression-free survival and response, although longer follow-up is required for a definitive statement on survival. Thus, docetaxel–carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  O. CAMARA and J. SEHOULI Controversies in the Management of Ovarian Cancer - Pros and Cons for Lymph Node Dissection in Ovarian Cancer Anticancer Res, July 1, 2009; 29(7): 2837 - 2843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Teneriello, P. C. Tseng, M. Crozier, C. Encarnacion, K. Hancock, M. J. Messing, K. A. Boehm, A. Williams, and L. Asmar Phase II Evaluation of Nanoparticle Albumin-Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer J. Clin. Oncol., March 20, 2009; 27(9): 1426 - 1431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Bookman, M. F. Brady, W. P. McGuire, P. G. Harper, D. S. Alberts, M. Friedlander, N. Colombo, J. M. Fowler, P. A. Argenta, K. De Geest, et al. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup J. Clin. Oncol., March 20, 2009; 27(9): 1419 - 1425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Hoskins Triple Cytotoxic Therapy for Advanced Ovarian Cancer: A Failed Application, Not a Failed Strategy J. Clin. Oncol., March 20, 2009; 27(9): 1355 - 1358. [Full Text] [PDF]
|
|
|
|
|
|
D. AOKI, Y. WATANABE, T. JOBO, K. USHIJIMA, K. HASEGAWA, N. SUSUMU, N. SUZUKI, R. AOKI, S. ISONISHI, S. SAGAE, et al. Favourable Prognosis with Modified Dosing of Docetaxel and Cisplatin in Japanese Patients with Ovarian Cancer Anticancer Res, February 1, 2009; 29(2): 561 - 566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. PECTASIDES, G. PAPAXOINIS, G. FOUNTZILAS, G. ARAVANTINOS, A. BAMIAS, N. PAVLIDIS, H.P. KALOFONOS, E. TIMOTHEADOU, E. SAMANTAS, E. BRIASOULIS, et al. Epithelial Ovarian Cancer in Greece: A Retrospective Study of 1,791 Patients by the Hellenic Cooperative Oncology Group (HeCOG) Anticancer Res, February 1, 2009; 29(2): 745 - 751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. G. Lin, A. Immaneni, W. M. Merritt, L. S. Mangala, S. W. Kim, M. M.K. Shahzad, Y. T.M. Tsang, G. N. Armaiz-Pena, C. Lu, A. A. Kamat, et al. Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth Clin. Cancer Res., September 1, 2008; 14(17): 5437 - 5446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V. Barrett, J. Paul, A. Hay, P. A. Vasey, S. B. Kaye, R. M. Glasspool, and On behalf of the Scottish Gynaecological Cancer Tr Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial Ann. Onc., May 1, 2008; 19(5): 898 - 902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Branford, P. Pantelidis, and J. R. Ross Ethnic Considerations in Pharmacogenetic Studies J. Clin. Oncol., April 1, 2008; 26(10): 1766 - 1767. [Full Text] [PDF]
|
|
|
|
|
|
M. Joerger, A. D.R. Huitema, D. J. Richel, C. Dittrich, N. Pavlidis, E. Briasoulis, J. B. Vermorken, E. Strocchi, A. Martoni, R. Sorio, et al. Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group Clin. Cancer Res., November 1, 2007; 13(21): 6410 - 6418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Maitland, M. J. Ratain, and N. J. Cox Interpreting P Values in Pharmacogenetic Studies: A Call for Process and Perspective J. Clin. Oncol., October 10, 2007; 25(29): 4513 - 4515. [Full Text] [PDF]
|
|
|
|
|
|
S. Marsh, J. Paul, C. R. King, G. Gifford, H. L. McLeod, and R. Brown Pharmacogenetic Assessment of Toxicity and Outcome After Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian Cancer J. Clin. Oncol., October 10, 2007; 25(29): 4528 - 4535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Ferrandina, M Ludovisi, R De Vincenzo, V Salutari, D Lorusso, M Colangelo, T Prantera, M. Valerio, and G Scambia Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study Ann. Onc., August 1, 2007; 18(8): 1348 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Forster, S. Kaye, A. Oza, I. Sklenar, A. Johri, W. Cheung, S. Zaknoen, and M. Gore A Phase Ib and Pharmacokinetic Trial of Patupilone Combined with Carboplatin in Patients with Advanced Cancer Clin. Cancer Res., July 15, 2007; 13(14): 4178 - 4184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. G. Lin, A. B. Kunnumakkara, A. Nair, W. M. Merritt, L. Y. Han, G. N. Armaiz-Pena, A. A. Kamat, W. A. Spannuth, D. M. Gershenson, S. K. Lutgendorf, et al. Curcumin Inhibits Tumor Growth and Angiogenesis in Ovarian Carcinoma by Targeting the Nuclear Factor-{kappa}B Pathway Clin. Cancer Res., June 1, 2007; 13(11): 3423 - 3430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O Tredan, J-F Geay, S Touzet, R Delva, B Weber, J Cretin, J Provencal, J Martin, L Stefani, E Pujade-Lauraine, et al. Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens Ann. Onc., February 1, 2007; 18(2): 256 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Markman New, Expanded, and Modified Use of Approved Antineoplastic Agents in Ovarian Cancer Oncologist, February 1, 2007; 12(2): 186 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Qian, W. J. LaRochelle, G. Ara, F. Wu, K. D. Petersen, A. Thougaard, M. Sehested, H. S. Lichenstein, and M. Jeffers Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol. Cancer Ther., August 1, 2006; 5(8): 2086 - 2095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Marsh, C. R. King, H. L. McLeod, J. Paul, G. Gifford, R. Brown, H. Green, C. Peterson, P. Soderkvist, P. Rosenberg, et al. ABCB1 2677G>T/A Genotype and Paclitaxel Pharmacogenetics in Ovarian Cancer. Clin. Cancer Res., July 1, 2006; 12(13): 4127 - 4129. [Full Text] [PDF]
|
|
|
|
|
|
A. D. Colevas Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck J. Clin. Oncol., June 10, 2006; 24(17): 2644 - 2652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Chi and R. R. Barakat Aggressive Surgery and Ovarian Cancer J. Clin. Oncol., May 20, 2006; 24(15): 2395 - 2396. [Full Text] [PDF]
|
|
|
|
|
|
G. D. Aletti and W. A. Cliby Importance of Surgical Aggressiveness in Advanced Ovarian Cancer J. Clin. Oncol., May 20, 2006; 24(15): 2397 - 2397. [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Krasner, M. Roche, N. S. Horowitz, J. G. Supko, S. I. Lee, and E. Oliva Case 11-2006 -- A 54-Year-Old Woman with a Mass in the Pelvis N. Engl. J. Med., April 13, 2006; 354(15): 1615 - 1625. [Full Text] [PDF]
|
|
|
|
|
|
S. C. Crawford, P. A. Vasey, J. Paul, A. Hay, J. A. Davis, and S. B. Kaye Does Aggressive Surgery Only Benefit Patients With Less Advanced Ovarian Cancer? Results From an International Comparison Within the SCOTROC-1 Trial J. Clin. Oncol., December 1, 2005; 23(34): 8802 - 8811. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Teodoridis, J. Hall, S. Marsh, H. D. Kannall, C. Smyth, J. Curto, N. Siddiqui, H. Gabra, H. L. McLeod, G. Strathdee, et al. CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer Cancer Res., October 1, 2005; 65(19): 8961 - 8967. [Abstract] [Full Text] [PDF]
|
|